Trial reportAnnals of surgery2004
Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery.
Trial report in Annals of surgery, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis.Critical care (London, England) · 2011Pooled it
- Review
- Dysregulation of systemic immunity and its clinical application in gastric cancer.Frontiers in immunology · 2024Review
- Harnessing interventions during the immediate perioperative period to improve the long-term survival of patients following radical gastrectomy.World journal of gastrointestinal surgery · 2023Review
- Morbidity and Mortality of Neutropenic Patients in Visceral Surgery: A Narrative Review.Cells · 2022Review
- An update on stem cell therapy for Asherman syndrome.Journal of assisted reproduction and genetics · 2020Review
- Harnessing cancer immunotherapy during the unexploited immediate perioperative period.Nature reviews. Clinical oncology · 2020Review
- Biomarkers for Evaluating the Inflammation Status in Patients with Cancer.Journal of gastric cancer · 2019Review
- Timing and Outcomes of Abdominal Surgery in Neutropenic Patients.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2019Observational
- Article
- Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors-Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses.International journal of molecular sciences · 2018Article
- Neutrophils in Tissue Trauma of the Skin, Bone, and Lung: Two Sides of the Same Coin.Journal of immunology research · 2018Review
- Neupogen and mesenchymal stem cells are the novel therapeutic agents in regeneration of induced endometrial fibrosis in experimental rats.Bioscience reports · 2017Article
- The Effects of Ex Vivo Administration of Granulocyte-Macrophage Colony-Stimulating Factor and Endotoxin on Cytokine Release of Whole Blood Are Determined by Priming Conditions.BioMed research international · 2017Article
- The Early Expression of HLA-DR and CD64 Myeloid Markers Is Specifically Compartmentalized in the Blood and Lungs of Patients with Septic Shock.Mediators of inflammation · 2016Article
- Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis.Critical care (London, England) · 2011Article
- Does granulocyte-colony stimulating factor administration induce damage or repair response in schistosomiasis?World journal of hepatology · 2010Article
- Immune response of severely injured patients--influence of surgical intervention and therapeutic impact.Langenbeck's archives of surgery · 2007Review
- Granulocyte colony-stimulating factor supports liver regeneration in a small-for-size liver remnant mouse model.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2007Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the effects of perioperative rhG-CSF administration on immune function in patients subjected to major surgery. SUMMARY BACKGROUND DATA: Severe trauma, such as major surgery, initiates acute immunodysfunction which predisposes the patient towards infectious complications.
methodsSixty patients undergoing elective surgery received either recombinant human granulocyte colony-stimulating factor/rh G-CSF (Filgrastim) or a placebo perioperatively. At several time points before and after the surgical intervention immunofunctional parameters were assessed. RESULTS Leukocyte counts and serum levels of anti-inflammatory mediators (IL-1ra and TNF-R) were increased in Filgrastim-treated patients, while the post-operative acute phase response was attenuated. Monocyte deactivation (reduced TNF-alpha release and HLA-DR expression) and lymphocyte anergy (impaired mitogenic proliferation and reduced TH1 lymphokine release) were blunted and the incidence and severity of infectious complications were reduced.
conclusionsThese results suggest that Filgrastim treatment reinforces innate immunity, enabling better prevention of infection. Thus, this unique combination of hematopoietic, anti-inflammatory and anti-infectious effects on the innate immune system warrants further study of clinical efficacy and sepsis prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.